BTIG Maintains Buy on vTv Therapeutics, Raises Price Target to $57

Benzinga Newsdesk www.benzinga.com Positive 86.2%

Neg 0% Neu 0% Pos 86.2%

BTIG analyst Kambiz Yazdi maintains vTv Therapeutics (NASDAQ:VTVT) with a Buy and raises the price target from $49 to $57.